Prima BioMed (PBMD) Announces European Patent for IMP731 Antibody

August 25, 2016 7:47 AM EDT
Get Alerts PBMD Hot Sheet
Trade PBMD Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Prima BioMed Ltd (NASDAQ: PBMD) announces the granting of patent number 2142210 entitled “Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease” by the European Patent Office.

The patent relates to Prima’s IMP731 antibody (originally developed by Immutep SAS). The granted claims provide protection for specific sequences of anti-LAG-3 antibodies and their use in depleting LAG-3+ T cells by complement dependent cytotoxicity (CDC) and antibody-dependent cell cytotoxicity (ADCC).

Rights for the development of the IMP731 antibody were granted in December 2010 to GSK, which has commenced first-in-human clinical trials of the proprietary antibody (GSK2831781) derived from IMP731.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, Litigation, Momentum Movers

Add Your Comment